pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ACADACADIA PHARMACEUTICALS INC

$ACAD18.67-0.43%
San Diego, CA, USupdated 14h ago

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
2
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 3: 1Marketed: 2Unknown: 2
1Phase 32Marketed2Unknown
Marketed
pimavanserin tartrate
Psychosis
Marketed
trofinetide
Rett Syndrome
Phase 3
remlifanserin
Alzheimer's Disease
drug
DAYBUE
1 INDICATIONS AND USAGE DAYBUE and DAYBUE STIX are indica…
drug
DAYBUE STIX
1 INDICATIONS AND USAGE DAYBUE and DAYBUE STIX are indica…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 4, 2026
earnings
$ACAD18.67-0.43%
13d ago
ACADIA PHARMACEUTICALS INC earnings
ACADIA PHARMACEUTICALS INC
→
view all catalysts →

Active trials

  • phase3ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Studyenrolling by invitationn=752
  • phase3Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndromecompletedn=175
  • phase2Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosisrecruitingn=180
  • phase3Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosisrecruitingn=126
  • phase2ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Responserecruitingn=153
  • phase3OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrometerminatedn=168
  • phase3ACP-204 in Adults With Alzheimer's Disease Psychosisrecruitingn=1,074
  • phase3Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorderterminatedn=209
🐶 Hiring Signal
No open roles indexed yet — view ACADIA PHARMACEUTICALS INC jobs →

News

  • Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
    This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.
    biospace · 1d ago
  • Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
    As both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is hopeful of seeing a therapy that can truly change the disease's path.
    biospace · 22d ago
  • Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
    Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
    biopharma_dive · 1mo ago
  • Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3
    Acadia Pharmaceuticals reported a Phase 2 failure in Alzheimer’s disease psychosis, but the company said it saw enough signal to continue forward into Phase 3 — with a caveat. The biotech’s experim…
    endpoints · 1mo ago
  • Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
    While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy bod…
    biospace · 1mo ago
  • Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
    Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…
    fiercebiotech · 1mo ago
  • An AI drug specialist zeroes in on rare forms of obesity
    Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…
    biopharma_dive · 2mo ago
  • On second try, Acadia drug gets nod from European regulators
    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
    biopharma_dive · 4mo ago
  • Celiac disease is entering a new era of therapeutic innovation
    For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.
    biopharma_dive · 5mo ago
  • Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
    In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.
    biopharma_dive · 5mo ago
view all news mentions →
identifiers
ticker
$ACAD
SEC CIK
0001070494
country
US
source
sec_tickers
top tags
Alzheimer's Disease1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?